Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


OBI Pharma To Forge Ahead With Cancer Vaccine In Face Of Study Failure

This article was originally published in Scrip

Executive Summary

Taiwanese biotech OBI Pharma plans to plough on with a Phase III study of its investigational cancer vaccine OBI-822/821, despite it failing to meet the primary endpoint in a Phase II/III study. The firm's share price fell by from TWD681 to close at TWD613 on Feb. 22 and slipped a further 9.95% to close at TWD522 on Feb. 23 on Taiwan's GreTai Securities Market following the news.


Related Content

Siamab, BI Team To ‘Attack’ Potential Of Carbohydrate Antibodies In Cancer





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts